Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

November 22, 2021
Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits Agreement will allow researchers to streamline development of novel mRNA therapeutics and vaccines SAN DIEGO,... READ MORE
November 15, 2021
Sirnaomics to Present at TIDES Europe 2021 Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
October 18, 2021
Sirnaomics to Present STP705, the Company’s Lead Drug Candidate, for the Treatment of Cutaneous Squamous Cell Carcinoma in situ, at the 2021 Fall Clinical Dermatology Conference The company will exhibit a Poster on Phase IIa clinical trial data for STP705 Sirnaomics,... READ MORE
September 21, 2021
Sirnaomics, Inc. to Present at TIDES USA 2021 Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
July 14, 2021
Sirnaomics Doses First Patient in Phase 2 Study of STP705 for Keloid Scar Prevention Expects to Report Initial Clinical Data in Second Half of 2021  Sirnaomics, Inc., a biopharmaceutical... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2021 by Sirnaomics, Inc.
Contact